Presentations relevant to development of IPPFPO

March 29 IP Task Force Meeting

•	Greg Milman	NIH NIAID
•	Robert Goldstein	JDRF
•	Steven Juhlsgaard	Genentech
•	Brad Margus	Perlegen
•	James Kovach	Buck Institute

April 27 IP Task Force Meeting

•	John Simpson	FTCR
•	Allan Robins	Novocell
•	David Gollaher	CHI
•	Joydeep Goswami	Invitrogen
•	Julie Meier Wright	San Diego Regional EDC

July 25 CIRM Commercial Sector Roundtable

•	Edward Baetge	Novocell
•	Sumit Chanda	Novartis Research Foundation
•	Bruce Cohen	Cellerant
•	Anne Hanham	Burrill & Company
•	Martin McGlynn	Stem Cells Inc.
•	Tom Okarma	Geron
•	Alan Smith	Cognate Bioservices
•	Michael West	Advanced Cell Technology

Milestones Achieved on the Path to Clinical Development of Geron's hESC-derived Glial Progenitor Cells for Spinal Cord Injury

Identification of clinical trial sites for Spinal cord injury Phase 1-2 trial

IND-enabling studies initiated

Scaled manufacturing & product release process estab.

Election of spinal cord injury as first therapeutic target

Establishment of hESC GMP Master Cell Bank at Geron

Establishment of cGMP production facility at Geron

Animal POC demonstrated for glial progenitors (SCI), cardiomyocytes (heart failure), hematopoietic cells (BMT), islets (diabetes)

Development of cryopreservation methods

Production of 8 functional cell types for animal testing

Development of 8 hESC differentiation protocols

Qualification of Geron hESC lines for human use

Not yet achieved:

- Completion of IND-enabling studies
- •FDA submission
- Initiation of Phase1-2 trial for SCI

Development of scalable serum and feeder-free methods to grow and expand hESCs

Generation of hESC Genomic Database with Celera (Geron owned)

Draft slides for IPTF 082906

Derivation of hESCs (Geron funded)